Press Releases

EMERYVILLE, Calif. , Feb. 9, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2022 financial results on Thursday, February 23, 2023 , after

EMERYVILLE, Calif. , Jan. 31, 2023 /PRNewswire/ -- Dynavax Technologies Corporation  (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, today announced that effective as of market open today, January 31, 2023 , its common

Preliminary full year 2022 HEPLISAV-B ® vaccine Net Product Revenue of approximately $126 million , representing 104% growth compared to 2021 Preliminary full year CpG 1018 ® adjuvant Net Product Revenue of approximately $588 million Maintained strong financial position with year-end cash and